TWiV 1182: Clinical update with Dr. Daniel Griffin

January 11, 2025

In his weekly clinical update, Dr. Griffin discusses how vaccination and vaccine hesitancy affects public health and disease spread in terms of mpox, the first human death from H5N1 in US, why one should not feed their pets raw pet food and the metapneumonia outbreak in China before reviewing the recent statistics on RSV, influenza and SARS-CoV-2 infections, the WasterwaterScan dashboard, where to find PEMGARDA, how nirmatrelvir-ritonavir/Paxlovid reduces adverse outcomes of COVID in patients with kidney disease, provides information for Columbia University Irving Medical Center’s long COVID treatment center, SARS-CoV-2 infection affects skin conditions including shingles and if long antiviral treatment affects long COVID.

Click arrow to play
Download TWiV 1182 (19 MB .mp3, 31 min)
Subscribe (free): Apple Podcasts, RSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

The post TWiV 1182: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.

Leave a Reply

Your email address will not be published. Required fields are marked *

0 comments on “TWiV 1182: Clinical update with Dr. Daniel Griffin

  1. Apropos of Dickson’s comment on anti-“gain of function” experiment/anti-transgenic crop similarities, researchers at Oregon State University are concerned a transgenic crop ban will halt their research: http://www.gazettetimes.com/news/local/collateral-damage-backers-say-m—would-only-ban/article_0fe04107-2e04-5e7c-9d22-d645c4293abf.html

    I agree 100% with the complaints about journal length restrictions. Even most scientists cannot access ScienceExpress articles until they make it into print. Science has an ‘article preview’ format where a one-page summary appears in the print journal, and the full article is just online. I agree with David Botstein that we should strive for articles that serve a didactic purpose (i.e. clearly explain things) rather than the current impress-the-reviewers paradigm.